Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2011 Results
Date:5/5/2011

r its products, product candidates or partnered products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's products, product candidates or partnered products in the marketplace, or a failure to become or remain profitable; Vanda's expectations regarding trends with respect to its costs and expenses; Vanda's inability to obtain the capital necessary to fund additional research and development activities; Vanda's failure to identify or obtain rights to new products or product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; limitations on Vanda's ability to utilize some or all of its prior net operating losses and research and development credits; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products or product candidates under its license and sublicense agreements and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2010 which is on file with the SEC and available on the SEC's website at www.sec.gov.  In addition to the risks described above and in Vanda's annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attrib
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
2. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
3. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
4. Vanda Pharmaceuticals Reports First Quarter 2009 Results
5. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
6. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
7. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
8. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
9. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
10. Vanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... to kill nematodes. Nematodes are microscopic parasitic roundworms, ... water, and inside other plants and animals. Nematicides ... volatility or other properties promoting migration through the ... more than 1,000 plant-parasitic nematodes. With more than ...
(Date:9/30/2014)... CORD:USE Cord Blood Bank – www.corduse.com ... entered into an Equity and Exclusive Services Agreement with ... of patented technologies for the isolation of human cord ... is performing Phase I/II clinical trials in ... using Tianhe,s Stem Cell Educator Therapy showing that the ...
(Date:9/30/2014)... and ROCKVILLE, Md., Sept. 30, 2014 ... focusing on commercializing market-relevant biohealth innovations and increasing access ... , announced today that venture capitalist, Tania Fernandez ... strategic advisor. Dr. Fernandez will be a member of ... which will provide up to $50 million in seed ...
(Date:9/30/2014)... Lyme Research Alliance (LRA), the ... at universities, today announced the awarding of seven grants ... and cure for Lyme and other tick-borne diseases. ... in its history—over 20 grant proposals—a 100 percent increase ... to receive so many solid applications from talented scientists ...
Breaking Biology Technology:Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4
... CAMBRIDGE, Mass., Jan. 13 Verenium Corporation,(Nasdaq: ... the development of next-generation cellulosic,ethanol and high-performance ... compliance with the continued listing requirements of ... that it had fallen out of,compliance with ...
... January 15th at 1:00PM PTNEW YORK, Jan. 13 ... announced that Michael S. Weiss, the Company,s Chairman and ... J.P. Morgan 27th Annual Healthcare Conference being held in ... Thursday, January 15th at 1:00pm PT and will be ...
... Jan. 13 Burnham Institute for Medical ... and license agreement with Johnson & Johnson ... The agreement is Burnham,s first broad-based partnership ... agreement, Burnham will provide J&JPRD with access ...
Cached Biology Technology:Verenium Regains Compliance With Nasdaq Continued Listing Requirement 2Verenium Regains Compliance With Nasdaq Continued Listing Requirement 3Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference 2Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2
(Date:9/29/2014)... that the exposure to tar tended to be lower ... Similarly, exposure to nicotine tended to be lower. ... cigarette in several countries around the world. Previous studies ... in the smoke of these cigarettes are lower than ... chemicals in the smoke are not necessarily linked to ...
(Date:9/29/2014)... According to a NASA story from 2009, "human activities in ... fire emissions issue. Palm oil is increasingly grown for use ... fats in processed foods. It has become the most widely ... in recent years to surpass that of soybean oil. , ... has to be cleared to grow the crop, and the ...
(Date:9/29/2014)... team says recently identified radiation detection properties of a ... for homeland security and medical advances. , In a ... of Optics Letters , UT Arlington Physics Professor ... to fabricate transparent nanoscintillators by heating nanoparticles composed of ... formed. A scintillator refers to a material that ...
Breaking Biology News(10 mins):Slim cigarette smokers not exposed to more harmful chemicals 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3
... 2008The 2008 American Society for Microbiology (ASM) BD ... presented to Stephen C. Edberg, Professor, Department of ... of Medicine, and Director, Clinical Microbiology Laboratory, Yale-New ... award recognizes a distinguished scientist for research accomplishments ...
... be the first recipient of a prestigious award given by ... Meeting of the Ecological Society of America on August 3. ... an outstanding record of informing their political decision-making with ecological ... figure that has a sharp appreciation for local and global ...
... 28, 2008The 2008 American Society for Microbiology (ASM) ... is presented to Steven A. Rosenberg, Chief of ... Services University of the Health Sciences, and Professor ... and Health Sciences. Sponsored by Abbott Laboratories Diagnostics ...
Cached Biology News:American Society for Microbiology honors Stephen C. Edberg 2American Society for Microbiology honors Steven A. Rosenberg 2
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
... Nucleon HT, 1 kit. Facilitates the ... paraffin-embedded sections and hard tissue requiring proteinase ... high quality DNA from 50 preparations of ... Category: DNA/RNA Synthesis & Purification, Purification and ...
Homo sapiens alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5), mRNA....
Phospho-p70 S6 Kinase (T229) Affinity Purified PAb...
Biology Products: